Accessibility Menu
BeOne Medicines Ag logo

BeOne Medicines Ag(NASDAQ) ONC

Market Cap$37.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+1,165%
5 Year+7%
1 Year+12%
1 Month+9%
$358.38
-1.19%
-4.30Today
After hours$358.00-$0.38 (-0.11%)
BeOne Medicines Ag last closing stock price
MetricPriceDate
Last closeUSD 358.262026-09-04
BeOne Medicines Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.31%USD 366.732026-08-28
1 month+9.38%USD 327.532026-08-05
3 month+32.64%USD 270.102026-06-05
Year to date+17.92%USD 303.812025-12-31
1 year+12.4%USD 318.732025-09-04
3 year+74.9%USD 204.842023-09-05
5 year+6.52%USD 336.322021-09-03
Since inception+1,165.04%USD 28.322016-02-03

BeOne Medicines Ag Financials at a Glance

Market Cap

$37.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.13B

Net Income (TTM)

$655.71M

EPS (TTM)

$5.69

P/E Ratio

62.96

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Price

$358.38

Volume

202,358

Open

$359.71

Previous Close

$358.26

Daily Range

$357.58 - $362.67

52-Week Range

$253.95 - $385.22

Estimated Earnings Date

Nov 5, 2026

ONC News

Two scientists looking at a monitor showing brain scans.

4 Best Cancer Stocks for 2026 and How to Invest

Keith SpeightsAug 16, 2026
SellAlert-Purple.png

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position

Jonathan PoncianoJul 22, 2026
Foolcom-Featured.png

BeOne Medicines (ONC) Q2 EPS Soars 924%

Motley Fool Markets TeamAug 6, 2025
MoonLake

Why BeiGene Stock Jumped Thursday

James HalleyApr 6, 2023
BioNTech

Why Shares of BeiGene Were Up Wednesday

James HalleyDec 1, 2022
GettyImages-1209892070

Is This Chinese Pharmaceutical Stock Worth the Risk?

James HalleyNov 3, 2022
biotech worker on assembly line

Why Shares of BeiGene Popped Today

Alex CarchidiJun 21, 2022
Scientists, Asian

This Chinese Stock Could Skyrocket 85%, According to Wall Street

Keith SpeightsMar 26, 2022
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BeOne Medicines Ag

BeOne Medicines AG makes innovative drugs to help cancer patients. The company develops treatments for blood and solid tumors. These medicines aim to improve health outcomes worldwide.

Winning the Cancer Fight

  • BRUKINSA: Small molecule inhibitor that blocks the Bruton’s Tyrosine Kinase protein to treat various blood cancers.
  • TEVIMBRA: Immunotherapy drug designed to help the immune system identify and attack solid tumors and blood cancers.
  • In-licensed Medicines: Portfolio of products including XGEVA and BLINCYTO licensed from Amgen for commercial sale in China.
  • BEQALZI: Targeted therapy recently approved in the U.S. for adult patients with relapsed mantle cell lymphoma.

Recent Growth and Expansion

  • Announced a $300 million expansion of the Hopewell, New Jersey, facility on July 23, 2026, to add manufacturing capabilities.
  • Secured accelerated approval from the Food and Drug Administration for BEQALZI in the U.S. on May 13, 2026.
  • Completed a name change and redomiciliation to Switzerland on May 27, 2025, to reflect its global identity.
  • Refinanced short-term debt through a $1 billion credit facility agreement with a syndicate of banks in November 2025.

Global Strength and Innovation

BeOne manages internal manufacturing and research centers to ensure a steady global supply of its medicines. The company creates its own drugs while partnering with other firms to grow its collection of cancer treatments.

Second Quarter 2026 Performance

  • Total revenue was $1.7 billion in the second quarter of 2026, up 29.6% year over year.
  • Global BRUKINSA sales reached $1.2 billion in the second quarter of 2026, up 31.4% year over year.
  • Income from operations rose to $325.0 million in the second quarter of 2026, up 269.9% year over year.
  • Cash, cash equivalents, and restricted cash totaled $5.3 billion as of June 30, 2026.

Company Evolution

BeOne has grown from a regional biotech into a global leader with specialized treatments sold in major international markets. Its focus on internal research and manufacturing allows it to scale its cancer drug portfolio effectively.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12,000

CEO

John V. Oyler, MBA

Website

beonemedicines.com

Headquarters

Basel, PA 4051, CH

ONC Financials

Key Financial Metrics (TTM)

Gross Margin

87.82%

Operating Margin

15.05%

Net Income Margin

10.68%

Return on Equity

14.27%

Return on Capital

7.03%

Return on Assets

7.17%

Earnings Yield

1.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$37.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

104.27M

Volume

202.36K

Avg. Volume

361.14K

Financials (TTM)

Gross Profit

$5.45B

Operating Income

$923.10M

EBITDA

$1.16B

Operating Cash Flow

$1.69B

Capital Expenditure

-$443.33M

Free Cash Flow

$1.24B

Cash & ST Invst.

$5.10B

Total Debt

$1.14B

BeOne Medicines Ag Performance Analysis

BeOne Medicines Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,414,238,59020.1%
20232023-12-31USD 2,456,641,66573.7%
20242024-12-31USD 3,812,152,13455.2%
20252025-12-31USD 5,357,163,91040.5%
BeOne Medicines Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.4%
Q42025-12-316.1%
Q12026-03-311.0%
Q22026-06-3012.7%
BeOne Medicines Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.4123.4%
20232023-12-31USD -8.44-56.5%
20242024-12-31USD -6.13-27.4%
20252025-12-31USD 2.54N/A
BeOne Medicines Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301517.4%
Q42025-12-31-50.0%
Q12026-03-31275.0%
Q22026-06-305.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.71B

+29.6%

Gross Profit

$1.53B

+33.0%

Gross Margin

89.76%

N/A

Market Cap

$37.36BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.11M

N/A

Employees

12,000

N/A

Net Income

$237.01M

+151.3%

EBITDA

$392.71M

+190.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.10B

+85.0%

Total Debt

$1.14B

+11.5%

Accounts Receivable

$1.07B

+21.7%

Inventory

$732.60M

+45.7%

Long Term Debt

$930.36M

+365.1%

Short Term Debt

$212.85M

-74.2%

Return on Assets

7.17%

N/A

Return on Invested Capital

13.14%

N/A

Free Cash Flow

$595.89M

+198.3%

Operating Cash Flow

$664.16M

+152.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALCAlcon Inc.
$70.50-2.19%
RMDResMed Inc.
$228.35-0.37%
AAgilent Technologies, Inc.
$150.84+0.57%
GEHCGE HealthCare Technologies Inc.
$68.86-1.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About ONC

What is the current price of BeOne Medicines Ag?

BeOne Medicines Ag is trading at $358.26 per share.

What is the 52-week range for BeOne Medicines Ag?

Over the past 52 weeks, BeOne Medicines Ag has traded between $253.95 and $385.22.

How much debt does BeOne Medicines Ag have?

As of the most recent reporting period, BeOne Medicines Ag reported total debt of $2.05B.

How much cash does BeOne Medicines Ag have on hand?

BeOne Medicines Ag reported $5.26B in cash and cash equivalents in its most recent financial results.

What is BeOne Medicines Ag’s dividend yield?

BeOne Medicines Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services